Search results for: 'mega providers'

13 May 2021  |  Global  |  Market Research

Post-COVID-19 Trends Disrupt the Global Contract Research Organization (CRO) Market

Increased Focus on Patient Centricity and Diversity in Clinical Trials Provide Growth Opportunities for CROs and Technology Vendors

Infographics

×

Frost & Sullivan presents post-COVID-19 growth opportunities and strategic imperatives in the contract research organization (CRO) market, covering the markets maturity, key participants, competitive landscape, and recent mergers and acquisitions. The study highlights key growth drivers and restraints, identifies initiatives by major global CROs, a...

The Healthcare industry has witnessed some of the largest mega-mergers in 2018 – mergers on the provider as well as the payer ends. While this has the potential to bring a shift in power centers in the ecosystem, each stakeholder has relied heavily on inorganic growth to maintain their stronghold. This Mergers and Acquisitions in Life Sciences Indu...

05 Feb 2021  |  North America  |  Market Research

Shifting Spotlight from Product- to Value-based Outcomes Intensifies Growth in the US Real-world Evidence IT Solutions Market

Early-stage R&D and Commercial Applications Fuel the Growth Pipeline

Infographics

×

The US healthcare industrys transition to a patient-centric model is moving rapidly with focus on outcomes and value; however, drug prices have increased and pharmaceutical research and development (R&D) productivity is at its lowest. The healthcare industry and IT solutions providers are finding real-world evidence (RWE) as a potential solution to...

This research identifies some the key developments across CAR-T cell therapies and provides insights across technological, IP, and investment landscapes. The study also provides an analysis of the competitive landscape while highlighting the key growth opportunities within the CAR-T cell therapy platform.

The global life sciences industry is onto a rocking start with the surge in CEO confidence from US tax reforms, rollicking equity markets and strengthening the global economy. Healthcare digitization, democratization creating explosion in patient data, emergence of value-based reimbursement models, and healthcare consumerism shifting the risk from ...

Frost & Sullivan provides comprehensive insights into the global biologics contract development and manufacturing organization (bio-CDMO) market, including emerging trends, growth opportunities, and profiles of leading bio-CDMOs and their business model evolution. The growth of next-generation biologics and personalized therapies and the emergence ...

12 Aug 2020  |  North America  |  Market Research

New Drug Development for Rare Pediatric Disorders Sustaining High Growth in the Global Orphan Drugs Market, 2019–2025

AI-powered Early Disease Diagnosis and Drug Repurposing will Create New Growth Opportunities

Infographics

×

Key Issues Addressed

Rare diseases have been an increasing area of focus as three waves have converged in recent years: genomic research and innovations becoming mainstream; the forthcoming regulatory policies and financial incentives put in place by the federal agencies; and the increasingly patient-centric and coordinated efforts of patient advocacy groups, caregive...

By 2023, biologics constituted 44% of the therapeutic pipeline, with antibodies and recombinant proteins as leading categories. Nevertheless, advancements in these fields decelerated, with most of the expansion happening in heterologous cell treatments, synthetic nucleic acids, and viruses. The global biologics pipeline will shift toward more compl...

Pharmaceutical drug discovery and development suffers from declining success rates with new molecules, and the rate of return has shrunk from 16% in 2011 to almost 11% in 2018. Frost & Sullivan finds that traditional solutions focused primarily on data from limited sources and rule-based computational techniques used to address the understanding of...